People: DexCom Inc (DXCM.OQ)

DXCM.OQ on NASDAQ Stock Exchange Global Select Market

13 Dec 2019
Change (% chg)

$1.83 (+0.91%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Skyler, Jay 

Dr. Jay S. Skyler serves as Independent Director of DexCom Inc., since September 2002. Dr. Skyler is a Professor of Medicine, Pediatrics and Psychology and Deputy Director of the Diabetes Research Institute at the University of Miami in Florida, where he has been employed since 1976. For 22 years, Dr. Skyler also served as Study Chairman for the National Institute of Diabetes & Digestive & Kidney Diseases Type 1 Diabetes clinical trials network. He is a past President of the American Diabetes Association and a past Vice-President of the International Diabetes Federation. Dr. Skyler served as a director of Amylin Pharmaceuticals, Inc. until its acquisition by Bristol-Myers Squibb Company in August 2012, and served as a director of MiniMed, Inc. until its acquisition by Medtronic, Inc. in 2001. Dr. Skyler received a B.S. from Pennsylvania State University and an M.D. from Jefferson Medical College. As a scholar and educator in the field of endocrinology, Dr. Skyler brings to the Board industry and technical experience directly related to DexCom’s research and development activities. In addition, Dr. Skyler’s board service with other public companies provides cross-board experience.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD 332,565
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 332,565

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Kevin Sayer


Quentin Blackford


Jake Leach


Donald Abbey


Andrew Balo


Richard Doubleday

As Of  31 Dec 2018